Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Amyloidosis

Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome

Bone Marrow Transplantation volume 33, pages 271–277 (2004)Cite this article

Summary:

Autologous stem cell transplantation (ASCT) for primary systemic amyloidosis (AL) produces high hematologic and organ responses. However, treatment-related mortality remains high and reported series are subject to selection bias. In all, 48 of 80 amyloid patients referred to our center had AL in the absence of myeloma, 26 of these 48 were deemed transplant candidates and 20 actually underwent ASCT. Transplant-related mortality has fallen from 50 to 20% since January 1999 due to better patient selection and prophylactic measures. Intent-to-treat organ responses were renal (46%), cardiac (25%) and liver (50%). Organ responses in patients who survived transplantation were renal (75%), cardiac (40%) and liver (100%). The 3-year OS post-ASCT was 56% with improved outcome predicted by a better performance status (P=0.08), normal ALP (P=0.08), nephrotic syndrome (P=0.01) and the absence of severe hypotension (P=0.01). The 3-year OS for all referred patients was 44% and this was not significantly better for transplant candidates. Patients with significant hypotension (systolic blood pressure ⩽90 mmHg) or poor performance status (ECOG >2) have an exceedingly high treatment-related mortality and should not be transplanted. For those undergoing ASCT, organ response rates appear promising, but conclusive evidence of improved survival for this select group of patients is still lacking and will require randomized trials.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Glenner GG, Terry W, Harada M et al. Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses. Science 1971; 172: 1150–1151.

    Article  CAS  PubMed  Google Scholar 

  2. Kyle RA, Gertz MA . Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45–59.

    CAS  PubMed  Google Scholar 

  3. Falk RH, Comenzo RL, Skinner M . The systemic amyloidoses. N Engl J Med 1997; 337: 898–909.

    Article  CAS  PubMed  Google Scholar 

  4. Kyle RA, Bayrd ED . Amyloidosis: review of 236 cases. Medicine (Baltimore) 1975; 54: 271–299.

    Article  CAS  Google Scholar 

  5. Kyle RA, Greipp PR . Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc 1983; 58: 665–683.

    CAS  PubMed  Google Scholar 

  6. Kyle RA, Gertz MA, Greipp PR et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood 1999; 93: 1062–1066.

    CAS  PubMed  Google Scholar 

  7. Skinner M, Anderson J, Simms R et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996; 100: 290–298.

    Article  CAS  PubMed  Google Scholar 

  8. Kyle RA, Gertz MA, Greipp PR et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336: 1202–1207.

    Article  CAS  PubMed  Google Scholar 

  9. Gertz MA, Lacy MQ, Lust JA et al. Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol 1999; 17: 262–267.

    Article  CAS  PubMed  Google Scholar 

  10. Sanchorawala V, Wright DG, Seldin DC et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001; 28: 637–642.

    Article  CAS  PubMed  Google Scholar 

  11. Dispenzieri A, Lacy MQ, Kyle RA et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 2001; 19: 3350–3356.

    Article  CAS  PubMed  Google Scholar 

  12. Saba N, Sutton D, Ross H et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant 1999; 24: 853–855.

    Article  CAS  PubMed  Google Scholar 

  13. Comenzo RL, Vosburgh E, Falk RH et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998; 91: 3662–3670.

    CAS  PubMed  Google Scholar 

  14. Comenzo RL, Vosburgh E, Simms RW et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood 1996; 88: 2801–2806.

    CAS  PubMed  Google Scholar 

  15. Moreau P, Milpied N, de Faucal P et al. High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement. Blood 1996; 87: 3063–3064.

    CAS  PubMed  Google Scholar 

  16. Moreau P, Leblond V, Bourquelot P et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 1998; 101: 766–769.

    Article  CAS  PubMed  Google Scholar 

  17. Comenzo RL, Falk R, Sanchorawala V et al. Treating AL amlyoidosis (AL) with dose-intensive melphalan: outcomes in 102 patients. Blood 1998; 92: 324a.

    Google Scholar 

  18. Gertz MA, Lacy MQ, Dispenzieri A . Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report. Bone Marrow Transplant 2000; 25: 465–470.

    Article  CAS  PubMed  Google Scholar 

  19. Sanchorawala V, Taper J, Seldin DC et al. High dose intravenous melphalan and autologous stem cell transplantation for the treatment of AL amyloidosis: morbidity and mortality. Blood 2001; 98: 860a.

    Article  Google Scholar 

  20. Casserly LF, Fadia A, Sanchorawala V et al. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney Int 2003; 63: 1051–1057.

    Article  CAS  PubMed  Google Scholar 

  21. Comenzo RL, Gertz MA . Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99: 4276–4282.

    Article  CAS  PubMed  Google Scholar 

  22. Lippman ME . High-dose chemotherapy plus autologous bone marrow transplantation for metastatic breast cancer. N Engl J Med 2000; 342: 1119–1120.

    Article  CAS  PubMed  Google Scholar 

  23. Sanchorawala V, Wright DG, Seldin DC et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Blood 2001; 98: 815a.

    Google Scholar 

  24. Comenzo RL, Sanchorawala V, Fisher C et al. Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br J Haematol 1999; 104: 553–559.

    Article  CAS  PubMed  Google Scholar 

  25. Gertz MA, Lacy MQ, Gastineau DA et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant 2000; 26: 963–969.

    Article  CAS  PubMed  Google Scholar 

  26. Hawkins PN, Aprile C, Capri G et al. Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis. Eur J Nucl Med 1998; 25: 701–708.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Princess Margaret Hospital, Toronto, Canada

    P N Mollee, A D Wechalekar, D L Pereira, N Franke, D Reece, C Chen & A K Stewart

Authors
  1. P N Mollee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A D Wechalekar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D L Pereira
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Franke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Reece
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A K Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A K Stewart.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mollee, P., Wechalekar, A., Pereira, D. et al. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Bone Marrow Transplant 33, 271–277 (2004). https://doi.org/10.1038/sj.bmt.1704344

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704344

Keywords

This article is cited by

Search

Advanced search

Quick links